Nicox S.A. (EPA:ALCOX)
0.3780
+0.0020 (0.53%)
Jun 3, 2026, 5:35 PM CET
Nicox Revenue
In the year 2025, Nicox had annual revenue of 16.77M EUR with 113.41% growth. Nicox had revenue of 15.25M in the half year ending December 31, 2025, with 779.71% growth.
Revenue
16.77M
Revenue Growth
+113.41%
P/S Ratio
1.98
Revenue / Employee
1.68M
Employees
10
Market Cap
33.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.77M | 8.91M | 113.41% |
| Dec 31, 2024 | 7.86M | 955.64K | 13.84% |
| Dec 31, 2023 | 6.90M | 3.63M | 111.04% |
| Dec 31, 2022 | 3.27M | -3.96M | -54.78% |
| Dec 31, 2021 | 7.23M | -5.67M | -43.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| genOway Société anonyme | 20.96M |
| Fermentalg | 13.38M |
| Poxel | 7.66M |
| Advicenne | 6.40M |
| MaaT Pharma | 4.52M |
| Adocia | 3.85M |
| Aelis Farma | 2.08M |
| OSE Immunotherapeutics | 1.78M |
Nicox News
- 1 year ago - Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights - GlobeNewsWire
- 1 year ago - Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results - GlobeNewsWire
- 2 years ago - Nicox Provides Second Quarter 2024 Update - GlobeNewsWire
- 2 years ago - Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results - GlobeNewsWire
- 2 years ago - Nicox Provides Fourth Quarter 2023 Financial and Business Highlights - GlobeNewsWire
- 2 years ago - Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Updates Key Milestones - GlobeNewsWire
- 3 years ago - Nicox Provides Second Quarter 2023 Financial and Business Highlights - GlobeNewsWire
- 3 years ago - Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis Showing Superiority over Latanoprost at the World Glaucoma Congress - GlobeNewsWire